Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume -, Issue -, Pages 115925
Publisher
Elsevier BV
Online
2023-11-07
DOI
10.1016/j.ejmech.2023.115925
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rezvilutamide: First Approval
- (2023) Susan J. Keam DRUGS
- Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.
- (2022) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Second generation androgen receptor antagonists and challenges in prostate cancer treatment
- (2022) Yanhua Chen et al. Cell Death & Disease
- Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
- (2022) Weijie Gu et al. LANCET ONCOLOGY
- Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies
- (2021) Wanxiao Sun et al. JOURNAL OF CONTROLLED RELEASE
- Piflufolastat F 18: Diagnostic First Approval
- (2021) Susan J. Keam Molecular Diagnosis & Therapy
- Advances in PSMA-targeted therapy for prostate cancer
- (2021) Fujin Wang et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Obesity and prostate cancer: A narrative review
- (2021) Rebekah L. Wilson et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Influence of Diet and Nutrition on Prostate Cancer
- (2020) Makoto Matsushita et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Recent progress in treating advanced prostate cancer
- (2020) Theodore Gourdin CURRENT OPINION IN ONCOLOGY
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
- (2020) Neal D. Shore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies
- (2020) Lucas Nogueira et al. MOLECULES
- FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA ‐Mutated Metastatic Castrate‐Resistant Prostate Cancer
- (2020) Mitchell S. Anscher et al. ONCOLOGIST
- The evolving role of diet in prostate cancer risk and progression
- (2019) Adeel Kaiser et al. CURRENT OPINION IN ONCOLOGY
- Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer
- (2019) Irena Saarinen et al. EJNMMI Research
- Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects
- (2019) Carlos Pérez-Ruixo et al. CLINICAL PHARMACOKINETICS
- Darolutamide: First Approval
- (2019) Anthony Markham et al. DRUGS
- PARP Inhibition in Cancer: An Update on Clinical Development
- (2019) Esha Sachdev et al. Targeted Oncology
- Role of chemotherapy in prostate cancer
- (2018) JeannyB Aragon-Ching et al. ASIAN JOURNAL OF ANDROLOGY
- Apalutamide: First Global Approval
- (2018) Zaina T. Al-Salama DRUGS
- Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
- (2018) Karim Fizazi et al. Clinical Genitourinary Cancer
- Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
- (2017) LE Dockery et al. OncoTargets and Therapy
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
- (2016) Matthew R. Smith et al. EUROPEAN UROLOGY
- Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy
- (2016) Zachary B Jenner et al. Future Oncology
- Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity
- (2016) Xiaowei Tai et al. JOURNAL OF DRUG TARGETING
- The role of the prostate in male fertility, health and disease
- (2016) Paolo Verze et al. Nature Reviews Urology
- TCDA: Practical Synthesis and Application in the Trifluoromethylation of Arenes and Heteroarenes
- (2016) Jian Wang et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Diagnostic and Therapeutic Strategies for Prostate Cancer
- (2016) Mary Nguyen-Nielsen et al. SEMINARS IN NUCLEAR MEDICINE
- The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells
- (2016) Reem T. Attia et al. PeerJ
- Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
- (2015) Jack Schalken et al. BJU INTERNATIONAL
- ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
- (2015) Karim Fizazi et al. Expert Review of Anticancer Therapy
- Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
- (2015) Bing Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- CYP17A1 inhibitors in castration-resistant prostate cancer
- (2015) Lissette Gomez et al. STEROIDS
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Androgen receptor: structure, role in prostate cancer and drug discovery
- (2014) MH Eileen Tan et al. ACTA PHARMACOLOGICA SINICA
- Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
- (2014) MarkN Stein et al. ASIAN JOURNAL OF ANDROLOGY
- Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function
- (2014) Jessica J. Field et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Androgen receptor antagonists for prostate cancer therapy
- (2014) Christine Helsen et al. ENDOCRINE-RELATED CANCER
- An Efficient Semi-Synthetic Method to Construct Docetaxel via Sterically Crowded Linear Side Chain Esterification
- (2013) Xin Shen et al. CHINESE JOURNAL OF CHEMISTRY
- The New Promise of FACBC Position Emission Tomography/Computed Tomography in the Localization of Disease Relapse After Radical Treatment for Prostate Cancer: Are We Turning to the Right Radiotracer?
- (2013) Riccardo Schiavina et al. EUROPEAN UROLOGY
- Advances in Androgen Receptor Targeted Therapy for Prostate Cancer
- (2013) Alia Ahmed et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Process Development of C–N Cross-Coupling and Enantioselective Biocatalytic Reactions for the Asymmetric Synthesis of Niraparib
- (2013) Cheol K. Chung et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation
- (2012) Akiyoshi Miwa et al. AMERICAN JOURNAL OF HEMATOLOGY
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Multkilogram Scale-Up of a Reductive Alkylation Route to a Novel PARP Inhibitor
- (2012) Adam T. Gillmore et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Mechanism of Androgen Receptor Antagonism by Bicalutamide in the Treatment of Prostate Cancer
- (2011) D. J. Osguthorpe et al. BIOCHEMISTRY
- The role of PARP in DNA repair and its therapeutic exploitation
- (2011) M Javle et al. BRITISH JOURNAL OF CANCER
- 2-(3- -Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
- (2011) Y. Chen et al. CLINICAL CANCER RESEARCH
- Cabazitaxel
- (2011) Cristian Villanueva et al. DRUGS
- The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature
- (2011) Guru Sonpavde et al. EUROPEAN UROLOGY
- Romidepsin: a novel histone deacetylase inhibitor for cancer
- (2011) Erin M Bertino et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor
- (2011) Kazuhiro Miwa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Abiraterone acetate
- (2011) Christopher J. Logothetis et al. NATURE REVIEWS DRUG DISCOVERY
- Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral PARP Inhibitor
- (2011) Debra J. Wallace et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- One Step Radiosynthesis of 6-[18F]Fluoronicotinic Acid 2,3,5,6-Tetrafluorophenyl Ester ([18F]F-Py-TFP): A New Prosthetic Group for Efficient Labeling of Biomolecules with Fluorine-18
- (2010) Dag E. Olberg et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
- (2010) Michael E. Jung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
- (2009) R. A. Daniel et al. CLINICAL CANCER RESEARCH
- Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
- (2009) Todd Morgan et al. CURRENT CANCER DRUG TARGETS
- The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research*
- (2009) F. Neumann EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)
- (2008) Sangeeta R. Banerjee et al. JOURNAL OF MEDICINAL CHEMISTRY
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines
- (2008) Anders Ullén et al. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now